The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Comparison of Pharmacological Treatments for Opioid-Dependent Adolescents: A Randomized Controlled Trial
Abstract
CONTEXT: The prevalence of heroin and other opioid use has markedly increased among adolescents in the last decade; however, virtually no research has been conducted to identify effective treatments for this population. OBJECTIVE: To evaluate the relative efficacy of 2 pharmacotherapies, the partial opioid agonist buprenorphine hydrochloride and the centrally active alpha(2)-adrenergic blocker clonidine hydrochloride, in the detoxification of opioid-dependent adolescents. DESIGN, SETTING, AND PATIENTS: A double-blind, double-dummy, parallel-groups randomized controlled trial conducted in a university-based research clinic from October 2001 to December 2003. Patients were a volunteer sample of 36 adolescents who met DSM-IV criteria for opioid dependence (ages 13-18 years eligible). INTERVENTIONS: Participants were randomly assigned to a 28-day, outpatient, medication-assisted withdrawal treatment with either buprenorphine or clonidine. Both medications were provided along with thrice weekly behavioral counseling and incentives contingent on opiate abstinence. Postdetoxification, all participants were offered the opportunity for continued treatment with the opiate antagonist, naltrexone hydrochloride. MAIN OUTCOME MEASURES: Treatment retention, opiate abstinence, and human immunodeficiency virus risk behavior, along with measures of withdrawal and medication effects. RESULTS: A significantly greater percentage of adolescents who received buprenorphine were retained in treatment (72%) relative to those who received clonidine (39%) (P<.05). For those in the buprenorphine group, a significantly higher percentage of scheduled urine test results were opiate negative (64% vs 32%; P = .01). Participants in both groups reported relief of withdrawal symptoms and drug-related human immunodeficiency virus risk behavior. Those in the buprenorphine condition generally reported more positive effects of the medication. No evidence of opioid intoxication or psychomotor impairment was observed. Sixty-one percent of participants in the buprenorphine condition and 5% of those in the clonidine group initiated treatment with naltrexone. CONCLUSION: Combining buprenorphine with behavioral interventions is significantly more efficacious in the treatment of opioid-dependent adolescents relative to combining clonidine and behavioral interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 2×
“Because of buprenorphine’s slow dissociation from the μ–opioid receptor, discontinuation of buprenorphine treatment results in reduced withdrawal symptoms relative to discontinuation of full agonists.(22-24) Numerous controlled trials have demonstrated that buprenorphine is safe and efficacious in alleviating opiate w…”
BackgroundClinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Behavior therapy for drug abuse: A controlled treatment outcome study
Azrin, N. H., McMahon, P. T., Donohue, B., Besalel, V. A., Lapinski, K. J., Kogan, E. S., Acierno, R. E., & Galloway, E. (1994) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)90166-x · Cited by 153
Clonidine in Child and Adolescent Psychiatry
HUNT, R. D., CAPPER, L., & O'CONNELL, P. (1990) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1990.1.87 · Cited by 127 · cited 2×
“These doses and dosing schedule with clonidine are similar to and in the low to moderate range of doses that have been used in opioid detoxification studies with adults(47,48) and in studies that have used clonidine in treating psychiatric disorders in adolescents.(38,39) All participants were also provided with the o…”
BackgroundFollow-up results of Supportive versus Behavioral Therapy for illicit drug use
Azrin, N. H., Acierno, R., Kogan, E. S., Donohue, B., Besalel, V. A., & Mcmahon, P. T. (1996) · Behaviour Research and Therapy · doi:10.1016/0005-7967(95)00049-4 · Cited by 100
Donohue, B., & Azrin, N. (2001) · Innovations in Adolescent Substance Abuse Interventions · doi:10.1016/b978-008043577-0/50030-4 · Cited by 62
Cited by
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions
Connery, H. S. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000075 · Cited by 576
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Drossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.279 · Cited by 470
The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
(2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000633 · Cited by 412
Research Review: What have we learned about adolescent substance use?
Gray, K. M., & Squeglia, L. M. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12783 · Cited by 383
“interventions: buprenorphine-naloxone maintenance to improve treatment retention and outcomes for opioid use disorder (Marsch et al., 2005; Woody et al., 2008), N-acetylycysteine as an adjunct to cessation counseling and contingency management for cannabis use disorder (Gray et al.”
Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., et al. (2008) · JAMA · doi:10.1001/jama.2008.574 · Cited by 361
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“An RCT compared buprenorphine with clonidine in detoxification of 36 opioid-dependent adolescents (13–18 years old; Marsch et al., 2005) (Ib).”
BackgroundBuprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Hadland, S. E., Wharam, J. F., Schuster, M. A., Zhang, F., Samet, J. H., & Larochelle, M. R. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.0745 · Cited by 294
Kraus, M. L., Alford, D. P., Kotz, M. M., Levounis, P., Mandell, T. W., Meyer, M., Salsitz, E. A., Wetterau, N., & Wyatt, S. A. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182312983 · Cited by 266
What Works in Substance Abuse Treatment Programs for Offenders?
Bahr, S. J., Masters, A. L., & Taylor, B. M. (2012) · The Prison Journal · doi:10.1177/0032885512438836 · Cited by 107
“In a 28-day outpatient treatment with either buprenorphine or clonidine, those receiving buprenorphine had significantly higher retention in treatment and higher percentages of opiate abstinence (Marsch et al., 2005).”
BackgroundPharmacological Treatment of Youth Substance Use Disorders
Squeglia, L. M., Fadus, M. C., McClure, E. A., Tomko, R. L., & Gray, K. M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0009 · Cited by 79
Dunn, K. E., Sigmon, S. C., Strain, E. C., Heil, S. H., & Higgins, S. T. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.033 · Cited by 65
“Three studies used contingency management (CM), a behavioral intervention that provides monetary-based incentives for urinalysis-verified drug abstinence, to increase opioid abstinence (Amass et al., 1994; Becker et al., 2001; Marsch et al., 2005).”
BackgroundAdolescent Substance Use Disorders
Simon, K. M., Levy, S. J., & Bukstein, O. G. (2022) · NEJM Evidence · doi:10.1056/evidra2200051 · Cited by 43
Interventions for Substance Use Disorders in Adolescents: A Systematic Review
Steele, D. W., Becker, S. J., Danko, K. J., Balk, E. M., Saldanha, I. J., Adam, G. P., Bagley, S. M., Friedman, C., Spirito, A., Scott, K., et al. (2020) · doi:10.23970/ahrqepccer225 · Cited by 34
Integrated Treatment of Adolescents with Co-occurring Depression and Substance Use Disorder
Hinckley, J. D., & Riggs, P. (2019) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2019.02.006 · Cited by 27
Metadata
- Authors
- Marsch, L. A., Bickel, W. K., Badger, G. J., Stothart, M. E., Quesnel, K. J., Stanger, C., & Brooklyn, J.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2005-10-01
- Volume
- 62
- Issue
- 10
- Pages
- 1157
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2049229004
- Cited by
- 205
- References
- 7
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.